Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Historical Stock Chart
6 Months : From Jul 2018 to Jan 2019
Acorda Therapeutics Inc. (ACOR) were down 14.8%, to $24.45, Wednesday afternoon as a federal appeals court denied the company's motion for an injunction in its patent litigation with generic drug companies. In 2017, after a district court upheld one patent for multiple sclerosis treatment Ampyra, but invalidated four others, Acorda said it would cut about 20% of its workforce. If the appeals court doesn't overturn the district court's decision by July 30, "multiple generic drug manufacturers may decide to launch at-risk generic versions of Ampyra," the company said in a filing. (firstname.lastname@example.org)
(END) Dow Jones Newswires
July 25, 2018 14:21 ET (18:21 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.